Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering Reinvesting In Sales After Cutbacks; “Selective” Support For Zetia

Executive Summary

Schering-Plough will begin to reverse cutbacks in its primary care sales force, CEO Fred Hassan told investors during a conference call July 23
Advertisement

Related Content

Schering’s External Alliances Improving “D” In R&D, CEO Hassan Says
J&J Will Maintain Rx Headcount Through 2004 Under Cost-Cutting Plan
Schering Sales Force Recruitment Is 80% Complete; Morale Remains High
The 10% Solution: Roche Cuts U.S. Sales Force, Schering Reduces Payroll
Schering Says Smaller Is Better: Flexibility Aids Turnaround Process
Schering Spares Sales, Manufacturing From Cost-Cutting
Schering/FDA Relations Are Priority For Hassan: GMPs, Asmanex On Agenda
Pharmacia II? Schering’s Hassan Brings In Former Colleagues; Zahn Leaves
Schering Sales Force Reduction Shows “Changing Dynamics” In U.S. Market
Schering Sales Force Reduction Shows “Changing Dynamics” In U.S. Market
Advertisement
UsernamePublicRestriction

Register

PS042215

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel